Alex Munns is an assistant portfolio manager and a senior analyst on the US Growth Equities Team with a focus on the health care sector. His in-depth fundamental research, idea generation and buy/sell recommendations are leveraged across all four of the strategies managed by the Driehaus US Growth Equities Team. Additionally, specific to the Driehaus Life Sciences strategy, Mr. Munns acts as an assistant portfolio manager and is also responsible for security selection, portfolio construction, and risk management.
Mr. Munns has been working with or investing in health care companies since 2011. Before joining Driehaus Capital Management in 2015, Mr. Munns worked in oncology commercialization and business development with Baxalta where he performed due diligence on assets across oncology and hematology. Prior to that, he worked in business development for Terumo Cardiovascular Systems, managing contracts between the company, its suppliers, and due diligence. Mr. Munns has also taught for Teach for America in Chicago.
Mr. Munns received a B.A. from Yale University and an M.B.A. from the University of Michigan Ross School of Business.
What's Up In Private Markets?
How Big Pharma Merger and Acquisition (M&A) Priorities Skew the Life Sciences Investment Landscape and Create Pockets of Exploitable Inefficiency
XBI and M2: One Variable in Assessing Where We Are In Biotech’s Correction